147.25 -0.05 (-0.03%)
After hours: 6:05PM EDT
|Bid||147.14 x 1000|
|Ask||147.19 x 800|
|Day's range||146.60 - 149.64|
|52-week range||109.16 - 157.00|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||28.09|
|Earnings date||16 Jul 2020|
|Forward dividend & yield||4.04 (2.75%)|
|Ex-dividend date||22 May 2020|
|1y target est||164.17|
On Friday, Legend Biotech (NASDAQ: LEGN) became the latest biotechnology start-up to pull off a surprisingly successful initial public offering. The cell-based cancer therapy developer originally intended to raise around $350 million, but investors eager to invest in a corner of the economy relatively unaffected by the COVID-19 pandemic piled in and pushed Legend's haul up to a stunning $424 million.
Stunning employment data fed into growing optimism about cities and states relaxing the coronavirus-related restrictions that have hobbled activity and crushed the jobs market.
J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.
The White House reportedly plans to route extra federal funds and other assistance to the companies developing those potential SARS-CoV-2 vaccines.
The contract development and manufacturing organization will support a number of SARS-CoV-2 vaccine candidates.
In the latest trading session, Johnson & Johnson (JNJ) closed at $148.25, marking a +0.72% move from the previous day.
Investing in stocks is risky. The company claims to be "one of the few future-proof stocks" available today. It's a pretty safe bet that energy will increasingly be produced using renewable sources such as hydroelectric, wind, and solar.
Wouldn't it have been great to get in on the ground floor of Johnson & Johnson? How much money would you have now if you had been in that group and invested $10,000 in J&J? Twenty years before Mick Jagger, Keith Richards, and the rest of the band released that song, Johnson & Johnson listed its shares on the New York Stock Exchange.
Before putting your money in a dividend stock, you'll want to make sure it meets certain criteria. Let's look into how to identify great dividend stocks, and then we'll turn our attention to one stock that's a great choice for income-seeking investors. There are several dividend-specific metrics to consider when looking for great dividend stocks.
J&J submitted its application to the European Medicines Agency (EMA) in November for the vaccine, which targets an Ebola strain that causes the disease in most people. The company in February said it was developing a coronavirus vaccine program with the help of the same technologies used in the experimental Ebola vaccine. The panel recommendation confirms the potential of the vaccine technology, Johan Van Hoof, managing director of J&J's Janssen unit said.
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
Dividend stocks are a great option for a retirement account since you're earning income simply for holding shares. The coronavirus pandemic caused many companies to cut or cancel dividends. While other businesses saw substantial revenue declines from the current economic slowdown, there were at least three that delivered revenue and dividend increases in these tough economic times.
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
Geopolitical rivalries, as well as practical considerations, are emerging as real hurdles in the race for a COVID treatment.
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.